Warm Autoimmune Hemolytic Anemia (WAIHA)- Epidemiology Forecast to 2030

Warm Autoimmune Hemolytic Anemia (WAIHA)- Epidemiology Forecast to 2030

  • May 2020 •
  • 100 pages •
  • Report ID: 5897615 •
  • Format: PDF
‘Warm Autoimmune Hemolytic Anemia (WAIHA)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Warm Autoimmune Hemolytic Anemia in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan
Study Period: 2017–2030

Warm Autoimmune Hemolytic Anemia Disease Understanding
Autoimmune hemolytic anemia (AIHA) is defined as the increased destruction of red blood cells (RBCs) in the presence of anti-RBC autoantibodies with or without complement activation. W-AIHA is the most common type of autoimmune hemolytic anemia, comprising ?70-80% of all adult cases and ?50% of the pediatric cases. More than half of these cases are called primary due to undefined etiology. In contrast, the rest is secondary to recognizable underlying disorders, such as lymphoproliferative syndromes—malignant diseases, including chronic lymphoblastic leukemia (CLL), non-Hodgkin’s lymphoma, and solid tumors.

Warm Autoimmune Hemolytic Anemia Epidemiology
The Warm Autoimmune Hemolytic Anemia (WAIHA) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. The epidemiology data for Warm Autoimmune Hemolytic Anemia are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Warm Autoimmune Hemolytic Anemia Epidemiology Segmentation
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalent Cases of AIHA, Diagnosed Prevalence of wAIHA, Type-specific Prevalence of wAIHA, Gender-specific Prevalence of wAIHA) scenario of Warm Autoimmune Hemolytic Anemia (WAIHA)in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2030.
The report also provides the epidemiology trends observed in the 7MM during the study period,along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to the report, the total number of prevalent cases of Warm Autoimmune Hemolytic Anemia (WAIHA) in 7 MM was found to be 82,045, in the year 2017.

Report Scope
• The report covers detailed overview of Warm Autoimmune Hemolytic Anemia explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool of Warm Autoimmune Hemolytic Anemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of the disease
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology by Total Prevalent Cases of AIHA, Diagnosed Prevalence of wAIHA, Type-specific Prevalence of wAIHA, Gender-specific Prevalence of wAIHA in 7MM

Key strengths
• 11 Year Forecast of Warm Autoimmune Hemolytic Anemia epidemiology
• 7MM Coverage
• Total prevalent cases of WAIHA
• Prevalent Cases according to segmentation: Total Prevalent Cases of AIHA, Diagnosed Prevalence of wAIHA, Type-specific Prevalence of wAIHA, Gender-specific Prevalence of wAIHA

Key assessments

• Patient Segmentation
• Disease Risk & Burden

• Risk of disease by the segmentation
• Factors driving growth in a specific patient population